Synergistic effect of adoptive immunotherapy and docetaxel inhibits tumor growth in a mouse model

Hu, Yuefeng; Liu, Jingwei; Cui, Peilin; Liu, Tao; Piao, Chunmei; Xu, Xianghong; Zhang, Qi-Ke; Xiao, Man; Lu, Yongcheng; Liu, Xuesong; Wang, Yue

doi:10.1016/j.cellimm.2019.104036

Cited by 11 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, recent evidences have shown that docetaxel was able to act on the tumour microenvironment favouring the priming of immune response. This mechanism supports the hypothesis that taxanes act synergically with immunotherapy, highlighting the importance of their use in clinical practice [7][8][9][10].…”

Section: Introductionsupporting

confidence: 83%

Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era

et al. 2021

View full text Add to dashboard Cite

Objective First-line therapy for metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) has been revolutionized by the introduction of anti-checkpoint monoclonal antibodies, which have shown a significant improvement in overall survival (OS) gaining approval in a first line setting. Efficacy and safety of first-line weekly chemotherapy, compared to 3-weeks treatment, was retrospectively evaluated in a frail patient population with R/M HNSCC with the aim to evaluate its role as part of a personalized first-line approach. Methods A total of 124 patients with locally incurable R/M HNSCC receiving weekly (21) or three-weekly (103) chemotherapy plus cetuximab in a first line setting from December 2010 to September 2020 were retrospectively reviewed. Treatment outcomes in terms of objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and toxicities were analysed. Results Patients in the three-week subgroup were ECOG PS 0 (39) and 1 (64) while patients in weekly group (21) were all PS 2. No significant differences were reported in terms of age, sex, smoking and previous alcohol abuse considering the two distinct subgroups. Moreover, no statistically significant difference was found in PFS and OS between the two treatment subgroups. The response rate was 35% (36 patients) and 34% (7 patients) in three-week and weekly treatment group, respectively. Seventy patients (68%) in the three-week group experienced chemotherapy-related toxicities, predominantly G3. In the weekly group a predominantly low-grade toxicity was found in a lower number of patients (52%). Conclusion The weekly schedule appears to be an active and safe strategy in frail patients with R/M HNSCC. Based on these data, a weekly schedule could be considered as a first line treatment in all frail patients excluded from pembrolizumab treatment and a study on the combination of weekly chemotherapy and immunotherapy should be performed.

show abstract

Section: Introductionsupporting

confidence: 83%

Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Furthermore, recent evidence have shown that docetaxel was able to act on the tumour microenvironment favouring the priming of immune response. This mechanism supports the hypothesis that taxanes act synergistically with immunotherapy, highlighting the importance of their use in clinical practice 7,8,9,10 .…”

Section: Introductionsupporting

confidence: 82%

Weekly Chemotherapy as First Line Treatment in Frail Head and Neck Cancer Patients in the Immunotherapy Era

Botticelli

Pomati

Cirillo

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective: First-line therapy for metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) has been revolutionized by the introduction of anti-checkpoint monoclonal antibodies, that have shown a significant improvement in overall survival (OS) gaining the approval in first line setting. Efficacy and safety of first-line weekly chemotherapy, compared to three-weeks treatment, was retrospectively evaluated in frail patients’ population with R/M HNSCC with the aim to evaluate its role as part of a personalized first-line approach.Methods: A total of 124 patients with locally incurable R/M HNSCC receiving weekly (21) or three-weekly (103) chemotherapy plus cetuximab in first line setting from December 2010 to September 2020 were retrospectively reviewed. Treatment outcomes in terms of objective response rate (ORR), progression-free survival (PFS), OS and toxicities were analyzed.Results: Patients in the three-week subgroup were ECOG PS 0 (39) and 1 (64) while patients (21) in weekly group were all PS 2. No significant differences were reported in terms of age, sex, smoking and previous alcohol abuse considering the two distinct subgroups. Moreover, no statistically significant difference was found in PFS and OS between the two treatment subgroups. The response rate was 35 % (36 patients) and 34 % (7 patients) in three-week and weekly treatment group, respectively. Seventy patients (68%) in the three-week group experienced chemotherapy-related toxicities, predominantly G3. In the weekly group a predominantly low-grade toxicity was found in a lower number of patients (52%).Conclusion: The weekly schedule appears an active and safe strategy in frail patients with R/M HNSCC. Based on our data, the weekly schedule could currently be considered in all frail patients and study of combination of weekly chemotherapy and immunotherapy should be performed.

show abstract

“…It was shown in vivo that L-Arg depletion accumulates MDSCs and prevents T cell proliferation (220). Interestingly, arginase inhibitors partially eliminate MDSCs which produce high levels of arginase ex vivo and can impede myeloid cell-mediated suppression in the TME and enhance TIL function (221,222).…”

Section: Metabolitesmentioning

confidence: 99%

The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses

2020

View full text Add to dashboard Cite

The success of cancer immunotherapy relies on the knowledge of the tumor microenvironment and the immune evasion mechanisms in which the tumor, stroma, and infiltrating immune cells function in a complex network. The potential barriers that profoundly challenge the overall clinical outcome of promising therapies need to be fully identified and counteracted. Although cancer immunotherapy has increasingly been applied, we are far from understanding how to utilize different strategies in the best way and how to combine therapeutic options to optimize clinical benefit. This review intends to give a contemporary and detailed overview of the different roles of immune cells, exosomes, and molecules acting in the tumor microenvironment and how they relate to immune activation and escape. Further, current and novel immunotherapeutic options will be discussed.

show abstract

Synergistic effect of adoptive immunotherapy and docetaxel inhibits tumor growth in a mouse model

Cited by 11 publications

References 31 publications

Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era

Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era

Weekly Chemotherapy as First Line Treatment in Frail Head and Neck Cancer Patients in the Immunotherapy Era

The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses

Contact Info

Product

Resources

About